Screener
4D Molecular Therapeutics FDMT Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Marketable securities, long-term | 66,739 | 111,379 |
| Property and equipment, net | 13,587 | 14,867 |
| Operating lease right-of-use assets, net | 17,357 | 18,143 |
| Other assets | 9,858 | 9,188 |
| Total assets | $512,905 | $566,711 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $14,692 | $11,159 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's deferred tax assets and other non-current assets?
- 4D Molecular Therapeutics (FDMT) reported deferred tax assets and other non-current assets of $9.86M in Q1 2026.
- How has 4D Molecular Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- 4D Molecular Therapeutics's deferred tax assets and other non-current assets increased by 40.0% year-over-year, from $7.04M to $9.86M.
- What is the long-term trend for 4D Molecular Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's deferred tax assets and other non-current assets has grown at a 72.5% compound annual growth rate (CAGR), from $602K to $9.19M.
Ask your AI about 4D Molecular Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude